top of page

IPAC-RS ROUNDTABLES - 2022

IPAC-RS is hosting a new Roundtable series in 2022, supplementing the podium presentations held at the IPAC-RS/RDD Joint session that addressed Regulatory, Science and Technology Innovations Enabling Novel and Improved OINDP Design, Development and Manufacturing. 

The second webinar in the series, Advancing Sustainability of Device and Container Closure Systems (Part I) is scheduled for Wednesday, November 30, 2022 at 10:30 AM - 12:00 PM US ET.   Part II will take place in January 2023.

 

 

 

This virtual roundtable will bring together pharmaceutical industry and supply chain representatives to discuss emerging ideas and approaches to advance sustainability of device and container closure system (CCS) components.  The roundtable aims to (i) describe and discuss what the industry is currently doing with respect to device and CCS sustainability for existing products, and (ii) start to identify goals and actions that the OINDP industry and its supply chain partners can achieve and drive regarding device and CCS sustainability, while continuing to advance the availability of high quality, safe and efficacious products to patients.    

Moderator:

  • Lee Nagao, Ph.D., Senior Director - Science, Regulatory & Policy, Faegre Drinker Biddle & Reath, LLP, IPAC-RS Secretariat

 

Panelists:

  • Edward Jackson, Device Development Team Leader, Kindeva Drug Delivery

  • Christian Pommereau, Principal Engineer Platform Technology , Sanofi

  • Marc Severin, Program Manager Sustainability and Innovation, Presspart

  • Beate Treffler, Regional Sales Manager Europe, Healthcare Polymer Solutions, Avient Colorants Germany GmbH

 

Webinar Program:

I.     Welcome and Overview of Webinar (10 minutes)

II.    Presentations (15 minutes each) 

 

1.    Sustainability from a Plastic Raw Material Solutions Perspective

  • Beate Treffler, Avient Colorants Germany GmbH

 

Sustainability has reached the healthcare industry. Although the amount of plastic waste is less significant, it cannot be ignored, and Healthcare leaders are taking measures. Negative image of plastics, the trend to use alternative materials and the need for reduction of carbon footprint are driving the discussion. 
This session will provide an insight into the possibilities and likelihood of success for potential measures and new solutions with plastic materials in healthcare applications.

 

2.    Contributing to More Sustainable Drug Delivery Devices

  • Marc Severin, H&T Presspart

 

The development of sustainable pharmaceutical products is always the challenge for the complete supply chains. As contract manufacturer, we need to cooperate with customers and suppliers to strive for responsible solutions. 
How can we start such partnerships and what do we need to consider to e.g. source more sustainable materials? 
In this session, I will show our strategic and also practical approach to set our position and to work on more sustainable supply and value chains.

3.     LCA for Devices, Eco-Design, Circularity

  • Christian Pommereau, Sanofi

As a healthcare provider SANOFI is committed to care for the planet and to minimize the environmental impacts of our products and activities while strengthening our resilience in the face of environmental changes. We have 3 main goals:


•    Build the road to carbon neutrality by 2030 and net zero by 2050
•    Limit our environmental footprint and adopt truly circular solutions 
•    Improve environmental profile of our products


On the last mentioned point, I’d like to give you an overview of Sanofi’s activities with regards to Life-Cycle Analysis application in existing and new products.

4.    Switching to Sustainable Materials for Current Devices 

  • Edward Jackson, Kindeva

    • Where do we start when setting out on the journey to move to sustainable materials for our existing devices. 

    • What does this actually mean and what do we need to do? 

    • This process appears complex or is it?  

  • This session will provide some insight and  points to consider when assessing what your company and your partners may need to do to successfully make this switch.

​​III.     Moderated Q&A Session with the Panelists (20 minutes)

Click here to view bios for the speakers.


Feel free to share the registration information with interested colleagues.

bottom of page